SCHEMBL2556566

SCHEMBL2556566

CC(C)(C)OC(=O)N1CCN(C(=O)c2ccc(B(O)O)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.65
MEN1 O00255 2/20 0.65
HDAC4 P56524 1/20 0.53
ABL1 P00519 1/20 0.52
RIN1 Q13671 1/20 0.52
EPHX2 P34913 1/20 0.51
POLB P06746 1/20 0.48
ALDH1A1 P00352 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47
CNR2 P34972 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
GPR119 Q8TDV5 2/20 0.45
GAA P10253 1/20 0.45
CRBN Q96SW2 1/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 1/20 0.44
SETD7 Q8WTS6 1/20 0.43
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29089126 0.96 KMT2A (0.61) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL3059699 0.96 KMT2A (0.72) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL8252454 0.85 KMT2A (0.72) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL15331662 0.84 CRBN (0.53) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL29188760 0.84 KMT2A (0.70) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL3900270 0.84 KMT2A (0.70) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL5537347 0.84 KMT2A (0.70) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL16026530 0.83 KMT2A (0.56) KMT2AMEN1HDAC4ABL1RIN1
SCHEMBL426841 0.83 MAPT (0.64) KMT2AMEN1ALDH1A1SMN1; SMN2HTT
SCHEMBL29950978 0.83 HPGD (0.57) KMT2AMEN1POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025106910-A1 DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR FLARE THERAPEUTICS INC. (US) 2025-05-22 WO disclosed
CN-116621839-A EZH2 degradation agent and preparation method and application thereof 四川大学 2023-08-22 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022140326-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 US disclosed
CN-110903286-B 4, 6-disubstituted pyridine [3,2-d ] pyrimidine compound and preparation and application thereof 沈阳药科大学 2021-09-24 CN disclosed
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2021-07-15 US disclosed
US-10995078-B2 Compounds and compositions for inhibition of FASN FORMA THERAPEUTICS, INC. (US) 2021-05-04 US disclosed
CN-112521369-A Compounds and compositions for inhibition of FASN 福马治疗股份有限公司 2021-03-19 CN disclosed
EP-3587406-B1 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER FORMA THERAPEUTICS INC (US) 2021-01-27 EP disclosed
US-20180050997-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2018-02-22 US disclosed
EP-2968316-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN Forma Therapeutics, Inc. (US) 2016-01-20 EP disclosed
US-20160002188-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2016-01-07 US disclosed
US-20160002188-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2016-01-07 US disclosed
US-20160002188-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2016-01-07 US disclosed
WO-2014164749-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. (US) 2014-10-09 WO disclosed
WO-2014164749-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. (US) 2014-10-09 WO disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050997-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD KMT2A 4741/4885MEN1 4365/4885HDAC4 2154/4885
US-20160002188-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD KMT2A 4741/4885MEN1 4365/4885HDAC4 2154/4885
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD KMT2A 4741/4885MEN1 4365/4885HDAC4 2154/4885
US-10995078-B2 Compounds and compositions for inhibition of FASN FASN, FABP1, SCD KMT2A 4666/4885MEN1 4044/4885HDAC4 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.